- Expands intellectual property portfolio and strengthens position as leading innovator in developing putative psychedelic compounds -
TORONTO--(BUSINESS WIRE)-- Cybin Inc. ( NEO:CYBN) ( NYSE American:CYBN) ( Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics TM today announced that it has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 17/394,038 related to CYB004, the Companys investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders. The allowed claims include other forms of deuterated psychedelic tryptamine, notably certain deuterated forms of DMT and 5-MeO-DMT. The patent, which is expected to expire in 2041 before consideration of any patent term extensions, covers composition of matter for the CYB004 drug substance as a putative new chemical entity.
The receipt of this Notice of Allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the Companys dedication to the discovery and development of differentiated psychedelic-based compounds for addressing mental health, said Doug Drysdale, Chief Executive Officer of Cybin. Once issued, this patent may have the opportunity to cover a broad range of claims supporting our IP in psychedelic medicine and further strengthen our emerging best-in-class position in this evolving industry.
According to the U.S. National Institute of Mental Health, anxiety disorders are one of the most common mental illnesses in the U.S., affecting 40 million adults, or approximately 18% of the population every year1. Despite the availability of many prescription medicines, these treatments are not equally efficacious in all patients with up to 50% of patients with general anxiety disorder failing to respond to first line treatments2. Current standardized treatments for anxiety disorders also require chronic administration of medicines that have a long time to onset and present several potential side effects including weight gain, gastrointestinal disturbances, sexual dysfunction and withdrawal symptoms.
CYB004 is a proprietary deuterated psychedelic tryptamine that has the potential to effectively treat anxiety disorders without the well-known side effects of the current treatment landscape, concluded Drysdale.
Cybin continues to pursue multiple opportunities to secure and support its patent position for research and development evaluating deuterated tryptamines for future psychedelic-based treatments for mental illnesses.
About Cybin Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Patent filings described herein are held by Cybin IRL Limited, a wholly owned subsidiary of Cybin.
Cautionary Notes and Forward-Looking Statements Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybins future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words believe, expect, aim, intend, plan, continue, will, may, would, anticipate, estimate, forecast, predict, project, seek, should or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Companys proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to potentially treat psychiatric disorders.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Companys operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company's management's discussion and analysis for the period ended September 30, 2021 and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on http://www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.
Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
1)
Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-335. doi:10.31887/DCNS.2015.17.3/bbandelow
2)
Ansara ED. Management of treatment-resistant generalized anxiety disorder. Ment Health Clin. 2020;10(6):326-334. Published 2020 Nov 5. doi:10.9740/mhc.2020.11.326
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005174/en/
See the original post:
- Psychedelics Companies in Oregon Will Have to Grapple With 280E - Business Insider - May 21st, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 16 - The Dales Report - May 21st, 2022
- Psychedelics and Mindfulness: The Future of Mental Health? | Microdose - Microdose Psychedelic Insights - May 21st, 2022
- CATALYST Summit: 3 Psychedelic Speakers to Catch This Weekend - Psychedelic Spotlight - May 21st, 2022
- 'I took ketamine to treat my severe depression' - iNews - May 21st, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 9 - The Dales Report - May 15th, 2022
- Psychedelic Patents are Broken Because the Patent System Is Broken - VICE - May 15th, 2022
- Magic mushrooms are on WeHos mind - WEHOville - May 15th, 2022
- Behind the Scenes on the First Study To Compare the Effects of LSD and Psilocybin - Technology Networks - May 15th, 2022
- Revitalist's Strategic Initiatives Continue to Exceed Expectations for Execution Giving Company Record High Revenues Since Opening in 2018. - Business... - May 15th, 2022
- MDMA as medicine: Stemming the tide of veteran suicides in Western North Carolina - Smoky Mountain News - May 15th, 2022
- Cybin's CYB0004 Shows Positive Preclinical Results Over ... - May 3rd, 2022
- Psychedelics played role in Wallace Falls hiker's death ... - May 3rd, 2022
- The Mainstream Healthcare VCs Dipping Their Toes Into Psychedelics - Business Insider - May 3rd, 2022
- LSD Is Back On Campus, But This Time It's Approved - Green Market Report - May 3rd, 2022
- Mixing mushrooms and alcohol: What you need to know - Medical News Today - May 3rd, 2022
- Mycotopia Therapies Partners with Public Policy Specialist PsychedelicsEUROPE to Explore Opportunities in the European Market - GlobeNewswire - May 3rd, 2022
- Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for... - May 3rd, 2022
- Bicycle Day: Honoring The Onset Of The Psychedelic Revolution As It Zooms Across The Globe - Forbes - April 15th, 2022
- Psilocybin Rewires the Brain for People with Depression - University of California, San Francisco - April 15th, 2022
- Field Trip Health Houston's psychedelic healing with ketamine helps patient with depressive anxiety - Houston Chronicle - April 15th, 2022
- Mental Health Week: Magnetic Stimulation, Psychedelics and Tai Chi How Treatments For Anxiety And Depression Are Growing - KPCC - April 15th, 2022
- Psychedelics Want To Win Over The Sleep Aid Market - Green Market Report - April 15th, 2022
- Terran Biosciences and Blumentech SL announce the acquisition of a patent portfolio covering the groundbreaking discoveries of prominent psychedelics... - April 15th, 2022
- Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds - Yahoo Finance - April 15th, 2022
- Experts discuss the intersections of cannabis, health and food - CSU Pueblo Today - April 15th, 2022
- Psychedelics - PMC - April 11th, 2022
- Psychedelics - PubMed - April 11th, 2022
- Peace with psychedelics: Palestinians, Israelis took ayahuasca - Big Think - April 11th, 2022
- Study maps psychedelic-induced changes in consciousness to specific regions of the brain - PsyPost - April 11th, 2022
- The Next Big Addiction Treatment - The New York Times - April 11th, 2022
- SABI Mind and Reverie Psychedelics Partner To Expand Research Into Psychedelic-Assisted Therapies - Benzi - Benzinga - April 11th, 2022
- Jaden Smith on His Trippy Summer '22 Collection and the Power of Mushrooms - Complex - April 11th, 2022
- Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022 - Business Wire - March 31st, 2022
- Psychedelics' Interaction With Psych Meds: More Q's Than A's - Medscape - March 31st, 2022
- The Insights Psychedelics Give You Arent Always True - March 18th, 2022
- Stage Set for Psychedelics Stock Boom: Here's Where ... - March 18th, 2022
- SXSW stage is a collision of weed, metaverse, NFTs, acid and saving the planet - PitchBook News & Analysis - March 18th, 2022
- Jaden Smith Recalls His Experience With Psychedelic Mushrooms: Everything Just Becomes So Beautiful - Koimoi - March 18th, 2022
- Michigan Activists Submit Psychedelics Decriminalization ... - March 17th, 2022
- Psychedelics and the Future of Psychiatry - March 17th, 2022
- Mind Cure Gives Up On Psychedelics, Fires C-Suite, And Reverts To Shell After Strategic Review - The Deep Dive - March 17th, 2022
- A Fully-Seated Audience Takes Post-Punk with the Psychedelic Furs - Cornell University The Cornell Daily Sun - March 17th, 2022
- 5 people who used psychedelics to treat PTSD describe their trips - Business Insider - March 15th, 2022
- What is Microdosing, and Does it Work? - The New York Times - March 15th, 2022
- Bolt's Breslow Teams With Psychedelics Founder on Crypto Pharma Startup - The Information - March 15th, 2022
- Enveric, University of Calgary to study psychedelic therapy - OutSourcing-Pharma.com - March 15th, 2022
- Psychedelic therapy integral to ancient societies may be coming to Pennsylvania - 90.5 WESA - March 15th, 2022
- The Bluntness Debuts The BLUNTNESS/100 Its Inaugural List of the 100 Most Influential People in Cannabis & Psychedelics - 69News WFMZ-TV - March 15th, 2022
- Former NFL Player Eben Britton On His New Book, And The Tools He Used To Rebuild His Life (Including Psychedelics) - The Dales Report - March 15th, 2022
- Made by Marlo: Max Ingersoll and the Meaning of Meditation - Harvard Independent - March 15th, 2022
- What are Psychedelics? - March 8th, 2022
- Get the Legal Psychedelics for Sale in the USA ... - March 8th, 2022
- Fireside Project manifests a $200K fund to improve access to careers in psychedelic health - TechCrunch - March 8th, 2022
- Oklahoma bill to study mental health effects of 'shrooms' advances - Oklahoman.com - March 8th, 2022
- Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data supporting novel... - March 8th, 2022
- Cybin Teams With Chopra Foundation To Foster Psychedelics Awareness - Benzinga - Benzinga - March 8th, 2022
- How My Drinking Was Used to Deny Me Treatment for Depression - Filter - March 8th, 2022
- Seelos Therapeutics: Year-End Results and Business Highlights Microdose - Microdose Psychedelic Insights - March 8th, 2022
- No worries: Severe anxiety disorders to get the Incannex, Monash Uni treatment via psychedelics within vir ... - Stockhead - March 8th, 2022
- Meet the 16 Most Influential Women Shaping the Future of Psychedelics - Business Insider - February 15th, 2022
- Psychedelics startups are taking on mental health - Fast Company - February 15th, 2022
- Psychedelics Are Trending: If You Are Seeing Psilocybin In The Headlines Everywhere, You Are Right! - Ben - Benzinga - February 15th, 2022
- Why theres a push to legalize psychedelic drug therapy in Missouri - KTVI Fox 2 St. Louis - February 15th, 2022
- Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders - Business Wire - February 15th, 2022
- Psychedelic-assisted therapy program coming to Vancouver Island University | CTV News - CTV News VI - February 15th, 2022
- Sponsor 'confident' cannabis banking will pass this year (Newsletter: February 14, 2022) - Marijuana Moment - February 15th, 2022
- Core One Labs' Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone... - February 15th, 2022
- IBN (InvestorBrandNetwork) Expands Collaboration With Microdose Psychedelic Insights to Serve as Official Media Sponsor for all 2022 Events - Yahoo... - February 9th, 2022
- Journey Colab Believes It Has The Formula For Addiction Treatment - The Dales Report - February 9th, 2022
- Psychedelics Without the Trip Could Be 'Healing Magic' for Mental Health - Singularity Hub - February 7th, 2022
- Utah Lawmakers Vote To Study Benefits Of Psychedelics In Treating Mental Health Disorders - Marijuana Moment - February 7th, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of January 31 - The Dales Report - February 7th, 2022
- Psychedelic Therapy and Suicide: A Myth Busted? - Medscape - February 7th, 2022
- Back to the future: Psychedelic drugs in ... - Harvard Health - February 1st, 2022
- Seattle Legalizes Psychedelics - The Seattle Medium - February 1st, 2022
- How to Change Your Mind - Wikipedia - February 1st, 2022
- The Psychedelic Drug Industry Appears To Have A New Sugar Daddy - The Dales Report - February 1st, 2022
- Increased psychedelic use during pandemic prompts new research - University of Miami - February 1st, 2022
- What Is Microdosing and Can It Help Mental Health? - PsychCentral.com - February 1st, 2022